CHRONIC KIDNEY DISEASE AND SELECTED ASPECTS OF KIDNEY RECIPIENTS MONITORING
DOI:
https://doi.org/10.56782/pps.14Keywords:
cardiovascular markers, chronic kidney disease, kidney transplantation, monitoringAbstract
Kidney diseases are an important challenge for nowadays medicine. Chronic kidney disease is classified as a “disease of affluence”, moreover the problem of kidney diseases is also increasing due to an aging of a population. Elderly people are a part of a population with high risk of kidney failure. Additionally, an occurrence of concomitant diseases, e.g. cardiovascular diseases, significantly hinders treatment and increases mortality in this group. Chronic kidney disease is progressive and finally leads to end-stage renal disease. In that case a life-saving method is renal replacement therapy – dialysis or kidney transplantation. Due to limited number of organs for transplantation, majority of patients with end-stage renal disease are treated with dialysis. Kidney transplantation is an optimal method of renal replacement therapy, because of the longest survival of patients, the best quality of life and because it is less expensive than dialysis. Monitoring of transplanted kidneys function aims to provide a long life of “new” organ. Early diagnosis of unsatisfactory graft function and rapid medical intervention is intended to prevent the loss of the transplanted organ. Monitoring of parameters such as eGFR, a concentration of immunosuppressive drugs or level of markers of cardiovascular diseases is an important part of treatment.
Downloads
References
KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013, 3, 1–150.
Ekser, B.; Cooper, D.K.; Tector, A.J. The need for xenotransplantation as a source of organs and cells for clinical transplantation. Int J Surg 2015, 23, 199-204, doi:10.1016/j.ijsu.2015.06.066. DOI: https://doi.org/10.1016/j.ijsu.2015.06.066
Ślubowska, K.; Durlik, M. Czynniki ryzyka sercowo-naczyniowego u biorców przeszczepu nerki. Forum Nefrol 2014, 7, 241–248
Hruby, Z. Nefrologia praktyczna; PZWL: Warszawa, 2001.
Szczeklik, A. Choroby wewnętrzne. Tom II; Medycyna praktyczna: Kraków, 2006.
Dębska-Ślizień, A.; Rutkowski, B.; Rutkowski, P.; Korejwo, G.; Gellert, R. Condition of renal replacement therapy in Poland-2016. 2018, 22, 1-8
Alsaad, K.O.; Herzenberg, A.M. Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update. J Clin Pathol 2007, 60, 18-26, doi:10.1136/jcp.2005.035592. DOI: https://doi.org/10.1136/jcp.2005.035592
Rodriguez-Iturbe, B.; Haas, M. Streptococcus pyogenes: Basic biology to clinical manifestations. Post-streptococcal glomerulonephritis; University of Oklahoma Health Sciences Center, Oklahoma City,: 2016.
Boils, C.L.; Nasr, S.H.; Walker, P.D.; Couser, W.G.; Larsen, C.P. Update on endocarditis-associated glomerulonephritis. Kidney Int 2015, 87, 1241-1249, doi:10.1038/ki.2014.424. DOI: https://doi.org/10.1038/ki.2014.424
Molina, M.; Sánchez, J.; Sevillano, Á.; Bengoa, I.; Gutiérrez, E.; Martínez, M.A.; Hernández, E.; Praga, M. Two cases of glomerulonephritis in one patient infected with the hepatitis C virus. Nefrologia 2013, 33, 593-600, doi:10.3265/Nefrologia.pre2013.May.12067.
Zand, L.; Fervenza, F.C.; Nasr, S.H.; Sethi, S. Membranoproliferative glomerulonephritis associated with autoimmune diseases. J Nephrol 2014, 27, 165-171, doi:10.1007/s40620-014-0049-0. DOI: https://doi.org/10.1007/s40620-014-0049-0
Liu, M.; Li, X.C.; Lu, L.; Cao, Y.; Sun, R.R.; Chen, S.; Zhang, P.Y. Cardiovascular disease and its relationship with chronic kidney disease. Eur Rev Med Pharmacol Sci 2014, 18, 2918-2926.
Ronco, C.; McCullough, P.; Anker, S.D.; Anand, I.; Aspromonte, N.; Bagshaw, S.M.; Bellomo, R.; Berl, T.; Bobek, I.; Cruz, D.N., et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2010, 31, 703-711, doi:10.1093/eurheartj/ehp507. DOI: https://doi.org/10.1093/eurheartj/ehp507
Tonelli, M.; Wiebe, N.; Culleton, B.; House, A.; Rabbat, C.; Fok, M.; McAlister, F.; Garg, A.X. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006, 17, 2034-2047, doi:10.1681/asn.2005101085. DOI: https://doi.org/10.1681/ASN.2005101085
Subbiah, A.K.; Chhabra, Y.K.; Mahajan, S. Cardiovascular disease in patients with chronic kidney disease: a neglected subgroup. Heart Asia 2016, 8, 56-61, doi:10.1136/heartasia-2016-010809. DOI: https://doi.org/10.1136/heartasia-2016-010809
Manjunath, G.; Tighiouart, H.; Coresh, J.; Macleod, B.; Salem, D.N.; Griffith, J.L.; Levey, A.S.; Sarnak, M.J. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003, 63, 1121-1129, doi:10.1046/j.1523-1755.2003.00838.x. DOI: https://doi.org/10.1046/j.1523-1755.2003.00838.x
Akchurin, O.M.; Kaskel, F. Update on inflammation in chronic kidney disease. Blood Purif 2015, 39, 84-92, doi:10.1159/000368940. DOI: https://doi.org/10.1159/000368940
Reddy, Y.S.; Kiranmayi, V.S.; Bitla, A.R.; Krishna, G.S.; Rao, P.V.; Sivakumar, V. Nitric oxide status in patients with chronic kidney disease. Indian J Nephrol 2015, 25, 287-291, doi:10.4103/0971-4065.147376. DOI: https://doi.org/10.4103/0971-4065.147376
De Gennaro Colonna, V.; Bianchi, M.; Pascale, V.; Ferrario, P.; Morelli, F.; Pascale, W.; Tomasoni, L.; Turiel, M. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule. Med Sci Monit 2009, 15, 91-101.
Förstermann, U.; Sessa, W.C. Nitric oxide synthases: regulation and function. Eur Heart J 2012, 33, 829-837, doi:10.1093/eurheartj/ehr304. DOI: https://doi.org/10.1093/eurheartj/ehr304
Crichton, R.R.; Wilmet, S.; Legssyer, R.; Ward, R.J. Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. J Inorg Biochem 2002, 91, 9-18, doi:10.1016/s0162-0134(02)00461-0. DOI: https://doi.org/10.1016/S0162-0134(02)00461-0
Modi, G.K.; Naik, N. Atherosclerosis in chronic kidney disease: Striking while the Iron is labile. Indian J Nephrol 2013, 23, 337-339.
Cornelissen, A.; Guo, L.; Sakamoto, A.; Virmani, R.; Finn, A.V. New insights into the role of iron in inflammation and atherosclerosis. EBioMedicine 2019, 47, 598-606, doi:10.1016/j.ebiom.2019.08.014. DOI: https://doi.org/10.1016/j.ebiom.2019.08.014
Palit, S.; Kendrick, J. Vascular calcification in chronic kidney disease: role of disordered mineral metabolism. Curr Pharm Des 2014, 20, 5829-5833. DOI: https://doi.org/10.2174/1381612820666140212194926
Schlieper, G.; Schurgers, L.; Brandenburg, V.; Reutelingsperger, C.; Floege, J. Vascular calcification in chronic kidney disease: an update. Nephrol Dial Transplant 2016, 31, 31-39,doi:10.1093/ndt/gfv111. DOI: https://doi.org/10.1093/ndt/gfv111
Sinnakirouchenan, R.; Holley, J.L. Peritoneal dialysis versus hemodialysis: risks, benefits, and access issues. Adv Chronic Kidney Dis 2011, 18, 428-432, doi:10.1053/j.ackd.2011.09.001. DOI: https://doi.org/10.1053/j.ackd.2011.09.001
Yang, F.; Khin, L.W.; Lau, T.; Chua, H.R.; Vathsala, A.; Lee, E.; Luo, N. Hemodialysis versus Peritoneal Dialysis: A Comparison of Survival Outcomes in South-East Asian Patients with End-Stage Renal Disease. PLoS One 2015, 10, e0140195, doi:10.1371/journal.pone.0140195. DOI: https://doi.org/10.1371/journal.pone.0140195
Weir, M.R.; Burgess, E.D.; Cooper, J.E.; Fenves, A.Z.; Goldsmith, D.; McKay, D.; Mehrotra, A.; Mitsnefes, M.M.; Sica, D.A.; Taler, S.J. Assessment and management of hypertension in transplant patients. J Am Soc Nephrol 2015, 26, 1248-1260, doi:10.1681/asn.2014080834. DOI: https://doi.org/10.1681/ASN.2014080834
Kraus, M.A.; Kansal, S.; Copland, M.; Komenda, P.; Weinhandl, E.D.; Bakris, G.L.; Chan, C.T.; Fluck, R.J.; Burkart, J.M. Intensive Hemodialysis and Potential Risks With Increasing Treatment. Am J Kidney Dis 2016, 68, S51-S58, doi:10.1053/j.ajkd.2016.05.020. DOI: https://doi.org/10.1053/j.ajkd.2016.05.020
Vikrant, S.; Guleria, R.C.; Kanga, A.; Verma, B.S.; Singh, D.; Dheer, S.K. Microbiological aspects of peritonitis in patients on continuous ambulatory peritoneal dialysis. Indian J Nephrol 2013, 23, 12-17, doi:10.4103/0971-4065.107188. DOI: https://doi.org/10.4103/0971-4065.107188
O'Connor, N.R.; Kumar, P. Conservative Management of End-Stage Renal Disease without Dialysis: A Systematic Review. Journal of Palliative Medicine 2012, 15, 228-235, doi:10.1089/jpm.2011.0207. DOI: https://doi.org/10.1089/jpm.2011.0207
Gętek, M.; Nowakowska- Zajdel, E. Quality of life of patients on dialysis and after renal transplantation. Ann Acad Med Siles 2010, 64, 23-30.
Biuletyn informacyjny. Centrum Organizacyjno - Koordynacyjne ds. Transplantacji "Poltransplant". 2018;1. www. poltransplant.pl/Download/Biuletyn_2018.pdf ( 21.08.2020).
Biuletyn informacyjny. Centrum Organizacyjno - Koordynacyjne ds. Transplantacji " Poltransplant ". 2020;1. www.poltransplant.pl/Download/Biuletyn2020.pdf (10.10.2020).
Gołąb, J.; Jakóbisiak, M.; Lasek, W.; Stokłosa, T. Immunologia; Towarzystwo Naukowe PWN: Warszawa, 2012.
Moreau, A.; Varey, E.; Anegon, I.; Cuturi, M.C. Effector mechanisms of rejection. Cold Spring Harb Perspect Med 2013, 3, a015461, doi:10.1101/cshperspect.a015461. DOI: https://doi.org/10.1101/cshperspect.a015461
Bhatti, A.B.; Usman, M. Chronic Renal Transplant Rejection and Possible Anti-Proliferative Drug Targets. Cureus 2015, 7, e376, doi:10.7759/cureus.376. DOI: https://doi.org/10.7759/cureus.376
Ghods, A.J. Living kidney donation: the outcomes for donors. Int J Organ Transplant Med 2010, 1, 63-71.
BTS/RA. Living Donor Kidney Transplantation Guidelines 2018 www.bts .org.uk.
KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. Transplantation 2017, 101, 1–109.
Abramowicz, D.; Cochat, P.; Claas, F.H.; Heemann, U.; Pascual, J.; Dudley, C.; Harden, P.; Hourmant, M.; Maggiore, U.; Salvadori, M., et al. European Renal Best Practice Guideline on kidney donor and recipient evaluation and perioperative care. Nephrol Dial Transplant 2015, 30, 1790-1797, doi:10.1093/ndt/gfu216. DOI: https://doi.org/10.1093/ndt/gfu216
Alelign, T.; Ahmed, M.M.; Bobosha, K.; Tadesse, Y.; Howe, R.; Petros, B. Kidney Transplantation: The Challenge of Human Leukocyte Antigen and Its Therapeutic Strategies. J Immunol Res 2018, 2018, 1-18, doi:10.1155/2018/5986740. DOI: https://doi.org/10.1155/2018/5986740
Stoumpos, S.; Jardine, A.G.; Mark, P.B. Cardiovascular morbidity and mortality after kidney transplantation. Transpl Int 2015, 28, 10-21, doi:10.1111/tri.12413. DOI: https://doi.org/10.1111/tri.12413
Durlik; M.; K., Z. Zalecenia dotyczące leczenia immunosupresyjnego po przeszczepieniu narządów unaczynionych. Fundacja Zjednoczeni dla Transplantacji: Warszawa 2016
KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009, Suppl 3, S1-155, doi:10.1111/j.1600-6143.2009.02834.x. DOI: https://doi.org/10.1111/j.1600-6143.2009.02834.x
van Sandwijk, M.S.; Bemelman, F.J.; Ten Berge, I.J. Immunosuppressive drugs after solid organ transplantation. Neth J Med 2013, 71, 281-289.
Muntean, A.; Lucan, M. Immunosuppression in kidney transplantation. Clujul Med 2013, 86, 177-180.
Wagner, M.; Earley, A.K.; Webster, A.C.; Schmid, C.H.; Balk, E.M.; Uhlig, K. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2015, CD007746, doi:10.1002/14651858.CD007746.pub2. DOI: https://doi.org/10.1002/14651858.CD007746.pub2
Friedewald, J.J.; Reese, P.P. The kidney-first initiative: what is the current status of preemptive transplantation? Adv Chronic Kidney Dis 2012, 19, 252-256, doi:10.1053/j.ackd.2012.05.001. DOI: https://doi.org/10.1053/j.ackd.2012.05.001
Rambod, M.; Shabani, M.; Shokrpour, N.; Rafii, F.; Mohammadalliha, J. Quality of life of hemodialysis and renal transplantation patients. Health Care Manag (Frederick) 2011, 30, 23-28, doi:10.1097/HCM.0b013e3182078ab6. DOI: https://doi.org/10.1097/HCM.0b013e3182078ab6
Singh, S.K.; Cole, E.H.; Kim, S.J. Delayed Graft Function and Kidney Transplantation. In Kidney Transplantation, Weir, M., Lerma, E., Eds. Springer, New York, NY: Kidney Transplantation, 2014. DOI: https://doi.org/10.1007/978-1-4939-0342-9_13
Florkowski, C.M.; Chew-Harris, J.S. Methods of Estimating GFR - Different Equations Including CKD-EPI. Clin Biochem Rev 2011, 32, 75-79.
Bartlomiejczyk, I.; Zochowska, D.; Sanko-Resmer, J.; Matuszewicz, D.; Paczek, L. Therapeutic monitoring of tacrolimus concentrations in blood of renal and liver transplant recipients: comparison of microparticle enzyme immunoassay and enzyme multiplied immunoassay methods. Transplant Proc 2006, 38, 94-96, doi:10.1016/j.transproceed.2005.12.042. DOI: https://doi.org/10.1016/j.transproceed.2005.12.042
Mohammadpour, N.; Elyasi, S.; Vahdati, N.; Mohammadpour, A.H.; Shamsara, J. A review on therapeutic drug monitoring of immunosuppressant drugs. Iran J Basic Med Sci 2011, 14, 485-498.
Dasgupta, A.; Khalil, S.A.; Johnson-Davis, K.L. Analytical Performance Evaluation of a New Cobas Tacrolimus Assay on Cobas e411 Analyzer: Comparison of Values Obtained by the CMIA
Tacrolimus Assay and a Liquid Chromatography Combined with Tandem Mass Spectrometric Method. Ann Clin Lab Sci 2016, 46, 204-208.
Morgan, P.E.; Brown, N.W.; Tredger, J.M. A direct method for the measurement of everolimus and sirolimus in whole blood by LCMS/MS using an isotopic everolimus internal standard. Ther Drug Monit 2014, 36, 358-365, doi:10.1097/FTD.0000000000000006. DOI: https://doi.org/10.1097/FTD.0000000000000006
Cravedi, P.; Heeger, P.S. Immunologic monitoring in transplantation revisited. Curr Opin Organ Transplant 2012, 17, 26-32, doi:10.1097/MOT.0b013e32834ee402. DOI: https://doi.org/10.1097/MOT.0b013e32834ee402
Townamchai, N.; Safa, K.; Chandraker, A. Immunologic monitoring in kidney transplant recipients. Kidney Res Clin Pract 2013, 32, 52-61, doi:10.1016/j.krcp.2013.04.002. DOI: https://doi.org/10.1016/j.krcp.2013.04.002
Bojanowska, M.; Białobrzeska, B. Native and transplanted kidney biopsy — holistic nursing care. Forum Nefrol 2010, 3, 317–325
Sawosz, M.; Bączkowska, T. Protocol biopsies of a transplanted kidney. 2012, 5 105–109
Tapia-Canelas, C.; Zometa, R.; López-Oliva, M.O.; Jiménez, C.; Rivas, B.; Escuin, F.; Yébenes, L.; Selgas, R. Complications associated with renal graft biopsy in transplant patients. Nefrologia 2014, 34, 115-119, doi:10.3265/Nefrologia.pre2013.Nov.12232.
Rao, N.N.; Coates, P.T. Cardiovascular Disease After Kidney Transplant. Semin Nephrol 2018, 38, 291-297, doi:10.1016/j.semnephrol.2018.02.008. DOI: https://doi.org/10.1016/j.semnephrol.2018.02.008
Alani, H.; Tamimi, A.; Tamimi, N. Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs. World J Nephrol 2014, 3, 156-168, doi:10.5527/wjn.v3.i4.156. DOI: https://doi.org/10.5527/wjn.v3.i4.156
Dosi, R.; Bhatt, N.; Shah, P.; Patell, R. Cardiovascular disease and menopause. J Clin Diagn Res 2014, 8, 62-64, doi:10.7860/JCDR/2014/6457.4009. DOI: https://doi.org/10.7860/JCDR/2014/6457.4009
Kolber, M.R.; Scrimshaw, C. Family history of cardiovascular disease. Can Fam Physician 2014, 60, 1016.
Muntner, P.; He, J.; Astor, B.C.; Folsom, A.R.; Coresh, J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005, 16, 529-538, doi:10.1681/ASN.2004080656. DOI: https://doi.org/10.1681/ASN.2004080656
Vlagopoulos, P.T.; Sarnak, M.J. Traditional and nontraditional cardiovascular risk factors in chronic kidney disease. Med Clin North Am 2005, 89, 587-611, doi:10.1016/j.mcna.2004.11.003. DOI: https://doi.org/10.1016/j.mcna.2004.11.003
Romero, J.R.; Morris, J.; Pikula, A. Stroke prevention: modifying risk factors. Therapeutic advances in cardiovascular disease 2008, 2, 287-303, doi:10.1177/1753944708093847. DOI: https://doi.org/10.1177/1753944708093847
Collins, P. Risk factors for cardiovascular disease and hormone therapy in women. Heart 2006, 92 Suppl 3, iii24-28, doi:10.1136/hrt.2005.071787. DOI: https://doi.org/10.1136/hrt.2005.071787
Lewington, S.; Clarke, R.; Qizilbash, N.; Peto, R.; Collins, R.; Collaboration, P.S. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360, 1903-1913. DOI: https://doi.org/10.1016/S0140-6736(02)11911-8
Aronow, W.S. Treatment of systemic hypertension. Am J Cardiovasc Dis 2012, 2, 160-170.
Schnohr, P.; Lange, P.; Scharling, H.; Jensen, J.S. Long-term physical activity in leisure time and mortality from coronary heart disease, stroke, respiratory diseases, and cancer. The Copenhagen City Heart Study. Eur J Cardiovasc Prev Rehabil 2006, 13, 173-179, doi:10.1097/01.hjr.0000198923.80555.b7. DOI: https://doi.org/10.1097/01.hjr.0000198923.80555.b7
Hap, K.; Madziarska, K.; Hap, W.; Mazanowska, O. Phenotypic risk factors for new-onset diabetes mellitus (NODAT) in renal transplant recipients. Postepy Hig Med Dosw (Online) 2014, 68, 1347-1351, doi:10.5604/17322693.1129186. DOI: https://doi.org/10.5604/17322693.1129186
Murchison, L.E. Hyperlipidaemia. Br Med J (Clin Res Ed) 1985, 290, 535-538. DOI: https://doi.org/10.1136/bmj.290.6467.535
Nelson, R.H. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care 2013, 40, 195-211, doi:10.1016/j.pop.2012.11.003. DOI: https://doi.org/10.1016/j.pop.2012.11.003
Rafieian-Kopaei, M.; Setorki, M.; Doudi, M.; Baradaran, A.; Nasri, H. Atherosclerosis: process, indicators, risk factors and new hopes. Int J Prev Med 2014, 5, 927-946.
Fischer, S.; Schatz, U.; Julius, U. Practical recommendations for the management of hyperlipidemia. Atheroscler Suppl 2015, 18, 194-198, doi:10.1016/j.atherosclerosissup.2015.02.029. DOI: https://doi.org/10.1016/j.atherosclerosissup.2015.02.029
Messner, B.; Bernhard, D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol 2014, 34, 509-515, doi:10.1161/ATVBAHA.113.300156. DOI: https://doi.org/10.1161/ATVBAHA.113.300156
Yusuf, S.; Hawken, S.; Ounpuu, S.; Dans, T.; Avezum, A.; Lanas, F.; McQueen, M.; Budaj, A.; Pais, P.; Varigos, J., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364, 937-952, doi:10.1016/S0140-6736(04)17018-9. DOI: https://doi.org/10.1016/S0140-6736(04)17018-9
Neale, J.; Smith, A.C. Cardiovascular risk factors following renal transplant. World J Transplant 2015, 5, 183-195, doi:10.5500/wjt.v5.i4.183. DOI: https://doi.org/10.5500/wjt.v5.i4.183
Kokkinos, P. Physical activity, health benefits, and mortality risk. ISRN Cardiol 2012, 2012, 718789, doi:10.5402/2012/718789. DOI: https://doi.org/10.5402/2012/718789
Klop, B.; Elte, J.W.; Cabezas, M.C. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 2013, 5, 1218-1240, doi:10.3390/nu5041218. DOI: https://doi.org/10.3390/nu5041218
Kubota, Y.; Evenson, K.R.; MacLehose, R.F.; Roetker, N.S.; Joshu, C.E.; Folsom, A.R. Physical Activity and Lifetime Risk of Cardiovascular Disease and Cancer. Med Sci Sports Exerc 2017, 8, 1599–1605, doi:10.1249/MSS.0000000000001274. DOI: https://doi.org/10.1249/MSS.0000000000001274
Romano, G.; Lorenzon, E.; Montanaro, D. Effects of exercise in renal transplant recipients. World J Transplant 2012, 2, 46-50, doi:10.5500/wjt.v2.i4.46. DOI: https://doi.org/10.5500/wjt.v2.i4.46
Orlandi, G.; Sofi, F.; Moscarelli, L.; Cirami, L.; Mancini, S.; Stefani, L. Exercise Prescription in Renal Transplant Recipients: From Sports Medicine Toward Multidisciplinary Aspects: A Pilot Study. J. Funct. Morphol. Kinesiol. 2020, 5, 10, doi:https://doi.org/10.3390/jfmk5010010. DOI: https://doi.org/10.3390/jfmk5010010
Ferguson, B. ACSM’s Guidelines for Exercise Testing and Prescription 9th Ed. 2014. The Journal of the Canadian Chiropractic Association 2014, 58, 328-328.
Małgorzewicz, S.; Ciechanowski, K.; Kozłowska, L.; Krzanowska, K.; Krzanowski, M.; Kaczkan, M.; Borek, P.; Jankowska, M.; Rutkowski, B.; Dębska-Ślizień, A. Nutrition recommendations in chronic kidney disease - the position of the working group of the Polish Nephrological Society. Forum Nefrologiczne 2019, 12, 240–278.
Currie, G.; Delles, C. Proteinuria and its relation to cardiovascular disease. Int J Nephrol Renovasc Dis 2013, 7, 13-24, doi:10.2147/IJNRD.S40522. DOI: https://doi.org/10.2147/IJNRD.S40522
Hillege, H.L.; Fidler, V.; Diercks, G.F.; van Gilst, W.H.; de Zeeuw, D.; van Veldhuisen, D.J.; Gans, R.O.; Janssen, W.M.; Grobbee, D.E.; de Jong, P.E., et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002, 106, 1777-1782, doi:10.1161/01.cir.0000031732.78052.81. DOI: https://doi.org/10.1161/01.CIR.0000031732.78052.81
Lee, W.H.; Hsu, P.C.; Chu, C.Y.; Lee, H.H.; Lee, M.K.; Lee, C.S.; Yen, H.W.; Lin, T.H.; Voon, W.C.; Lai, W.T., et al. Anemia as an Independent Predictor of Adverse Cardiac Outcomes in Patients with Atrial Fibrillation. Int J Med Sci 2015, 12, 618-624, doi:10.7150/ijms.11924. DOI: https://doi.org/10.7150/ijms.11924
Durlik, M. Patogeneza i klinika niedokrwistości u chorych po przeszczepieniu nerki. Forum Nefrol. 2010, 3, 298-304
Karthikeyan, V.; Karpinski, J.; Nair, R.C.; Knoll, G. The burden of chronic kidney disease in renal transplant recipients. Am J Transplant 2004, 4, 262-269. DOI: https://doi.org/10.1046/j.1600-6143.2003.00315.x
Hariharan, S. Recommendations for outpatient monitoring of kidney transplant recipients. Am J Kidney Dis 2006, 47, S22-36, doi:10.1053/j.ajkd.2005.12.046. DOI: https://doi.org/10.1053/j.ajkd.2005.12.046
Sarnak, M.J.; Tighiouart, H.; Manjunath, G.; MacLeod, B.; Griffith, J.; Salem, D.; Levey, A.S. Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol 2002, 40, 27-33. DOI: https://doi.org/10.1016/S0735-1097(02)01938-1
Cervantes Gracia, K.; Llanas-Cornejo, D.; Husi, H. CVD and Oxidative Stress. J Clin Med 2017, 6, 22, doi:10.3390/jcm6020022. DOI: https://doi.org/10.3390/jcm6020022
Tabriziani, H.; Lipkowitz, M.S.; Vuong, N. Chronic kidney disease, kidney transplantation and oxidative stress: a new look to successful kidney transplantation. Clin Kidney J 2018, 11, 130-135, doi:10.1093/ckj/sfx091. DOI: https://doi.org/10.1093/ckj/sfx091
Sezer, S.; Akcay, A.; Ozdemir, F.N.; Kulah, E.; Arat, Z.; Haberal, M. Post-transplant C-reactive protein monitoring can predict chronic allograft nephropathy. Clin Transplant 2004, 18, 722-725, doi:10.1111/j.1399-0012.2004.00286.x. DOI: https://doi.org/10.1111/j.1399-0012.2004.00286.x
Kaptoge, S.; White, I.R.; Thompson, S.G.; Wood, A.M.; Lewington, S.; Lowe, G.D.; Danesh, J.; Collaboration, F.S. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. Am J Epidemiol 2007, 166, 867-879, doi:10.1093/aje/kwm191. DOI: https://doi.org/10.1093/aje/kwm191
Ozdemir, N.F.; Elsurer, R.; Ibis, A.; Arat, Z.; Haberal, M. Serum Creactive protein surge in renal transplant recipients: link with allograft survival. Transplant Proc 2007, 39, 934-937, doi:10.1016/j.transproceed.2007.02.023. DOI: https://doi.org/10.1016/j.transproceed.2007.02.023
Vanholder, R.C.; Eloot, S.; Glorieux, G.L. Future Avenues to Decrease Uremic Toxin Concentration. Am J Kidney Dis 2016, 67, 664-676, doi:10.1053/j.ajkd.2015.08.029. DOI: https://doi.org/10.1053/j.ajkd.2015.08.029
Vanholder, R.; Van Laecke, S.; Glorieux, G. What is new in uremic toxicity? Pediatr Nephrol 2008, 23, 1211-1221, doi:10.1007/s00467-008-0762-9. DOI: https://doi.org/10.1007/s00467-008-0762-9
Barreto, F.C.; Stinghen, A.E.; de Oliveira, R.B.; Franco, A.T.; Moreno, A.N.; Barreto, D.V.; Pecoits-Filho, R.; Drüeke, T.B.; Massy, Z.A. The quest for a better understanding of chronic kidney disease complications: an update on uremic toxins. J Bras Nefrol 2014, 36, 221-235. DOI: https://doi.org/10.5935/0101-2800.20140033
Cha, R.H.; Kang, S.W.; Park, C.W.; Cha, D.R.; Na, K.Y.; Kim, S.G.; Yoon, S.A.; Han, S.Y.; Chang, J.H.; Park, S.K., et al. A Randomized, Controlled Trial of Oral Intestinal Sorbent AST-120 on Renal Function Deterioration in Patients with Advanced Renal Dysfunction. Clin J Am Soc Nephrol 2016, 11, 559-567, doi:10.2215/CJN.12011214. DOI: https://doi.org/10.2215/CJN.12011214
Aldámiz-Echevarría, L.; Andrade, F. Asymmetric dimethylarginine, endothelial dysfunction and renal disease. Int J Mol Sci 2012, 13, 11288-11311, doi:10.3390/ijms130911288. DOI: https://doi.org/10.3390/ijms130911288
Valkonen, V.P.; Päivä, H.; Salonen, J.T.; Lakka, T.A.; Lehtimäki, T.; Laakso, J.; Laaksonen, R. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001, 358, 2127-2128, doi:10.1016/S0140-6736(01)07184-7. DOI: https://doi.org/10.1016/S0140-6736(01)07184-7
Willeit, P.; Freitag, D.F.; Laukkanen, J.A.; Chowdhury, S.; Gobin, R.; Mayr, M.; Di Angelantonio, E.; Chowdhury, R. Asymmetric dimethylarginine and cardiovascular risk: systematic review and meta-analysis of 22 prospective studies. J Am Heart Assoc 2015, 4, e001833, doi:10.1161/JAHA.115.001833. DOI: https://doi.org/10.1161/JAHA.115.001833
Zoccali, C.; Bode-Böger, S.; Mallamaci, F.; Benedetto, F.; Tripepi, G.; Malatino, L.; Cataliotti, A.; Bellanuova, I.; Fermo, I.; Frölich, J., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001, 358, 2113-2117. DOI: https://doi.org/10.1016/S0140-6736(01)07217-8
Ravani, P.; Tripepi, G.; Malberti, F.; Testa, S.; Mallamaci, F.; Zoccali, C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005, 16, 2449-2455, doi:10.1681/ASN.2005010076. DOI: https://doi.org/10.1681/ASN.2005010076
Lau, W.L.; Vaziri, N.D. Urea, a true uremic toxin: the empire strikes back. Clin Sci (Lond) 2017, 131, 3-12, doi:10.1042/CS20160203. DOI: https://doi.org/10.1042/CS20160203
Ndrepepa, G. Uric acid and cardiovascular disease. Clin Chim Acta 2018, 484, 150-163, doi:10.1016/j.cca.2018.05.046. DOI: https://doi.org/10.1016/j.cca.2018.05.046
Currò, M.; Gugliandolo, A.; Gangemi, C.; Risitano, R.; Ientile, R.; Caccamo, D. Toxic effects of mildly elevated homocysteine concentrations in neuronal-like cells. Neurochem Res 2014, 39, 1485-1495, doi:10.1007/s11064-014-1338-7. DOI: https://doi.org/10.1007/s11064-014-1338-7
Ye, Z.; Zhang, Q.; Li, Y.; Wang, C.; Zhang, J.; Ma, X.; Peng, H.; Lou, T. High Prevalence of Hyperhomocysteinemia and Its Association with Target Organ Damage in Chinese Patients with Chronic Kidney Disease. Nutrients 2016, 8, 645, doi:10.3390/nu8100645. DOI: https://doi.org/10.3390/nu8100645
Baszczuk, A.; Kopczyński, Z. Hyperhomocysteinemia in patients with cardiovascular disease. Postepy Hig Med Dosw (Online) 2014, 68, 579-589, doi:10.5604/17322693.1102340. DOI: https://doi.org/10.5604/17322693.1102340
Ganguly, P.; Alam, S.F. Role of homocysteine in the development of cardiovascular disease. Nutr J 2015, 14, 6, doi:10.1186/1475-2891-14-6. DOI: https://doi.org/10.1186/1475-2891-14-6
van Ballegooijen, A.J.; Reinders, I.; Visser, M.; Brouwer, I.A. Parathyroid hormone and cardiovascular disease events: A systematic review and meta-analysis of prospective studies. Am Heart J 2013, 165, 655-664, 664.e651-655, doi:10.1016/j.ahj.2013.02.014. DOI: https://doi.org/10.1016/j.ahj.2013.02.014
Goettsch, C.; Iwata, H.; Aikawa, E. Parathyroid hormone: critical bridge between bone metabolism and cardiovascular disease. Arterioscler Thromb Vasc Biol 2014, 34, 1333-1335, doi:10.1161/ATVBAHA.114.303637. DOI: https://doi.org/10.1161/ATVBAHA.114.303637
Korytowska, N.; Wyczałkowska-Tomasik, A.; Wiśniewska, A.; Pączek, L.; Giebułtowicz, J. Development of the LC-MS/MS method for determining the p-cresol level in plasma. J Pharm Biomed Anal 2019, 167, 149-154, doi:10.1016/j.jpba.2019.01.041. DOI: https://doi.org/10.1016/j.jpba.2019.01.041
Leong, S.C.; Sirich, T.L. Indoxyl Sulfate-Review of Toxicity and Therapeutic Strategies. Toxins (Basel) 2016, 8, 358, doi:10.3390/toxins8120358. DOI: https://doi.org/10.3390/toxins8120358
Gryp, T.; Vanholder, R.; Vaneechoutte, M.; Glorieux, G. p-Cresyl Sulfate. Toxins (Basel) 2017, 9, 52, doi:10.3390/toxins9020052. DOI: https://doi.org/10.3390/toxins9020052
Korytowska, N.; Sankowski, B.; Wyczałkowska-Tomasik, A.; Pączek, L.; Wroczyński, P.; Giebułtowicz, J. The utility of saliva testing in the estimation of uremic toxin levels in serum. Clin Chem Lab Med 2018, 57, 230-237, doi:10.1515/cclm-2018-0087. DOI: https://doi.org/10.1515/cclm-2018-0087
Chiu, C.A.; Lu, L.F.; Yu, T.H.; Hung, W.C.; Chung, F.M.; Tsai, I.T.; Yang, C.Y.; Hsu, C.C.; Lu, Y.C.; Wang, C.P., et al. Increased levels of total P-Cresylsulphate and indoxyl sulphate are associated with coronary artery disease in patients with diabetic nephropathy. Rev Diabet Stud 2010, 7, 275-284, doi:10.1900/RDS.2010.7.275. DOI: https://doi.org/10.1900/RDS.2010.7.275
Wang, Z.; Klipfell, E.; Bennett, B.J.; Koeth, R.; Levison, B.S.; DuGar, B.; Feldstein, A.E.; Britt, E.B.; Fu, X.; Chung, Y.-M., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011, 472, 57-63, doi:10.1038/nature09922. DOI: https://doi.org/10.1038/nature09922
Tang, W.H.; Wang, Z.; Kennedy, D.J.; Wu, Y.; Buffa, J.A.; AgatisaBoyle, B.; Li, X.S.; Levison, B.S.; Hazen, S.L. Gut microbiotadependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 2015, 116, 448-455, doi:10.1161/CIRCRESAHA.116.305360. DOI: https://doi.org/10.1161/CIRCRESAHA.116.305360
Chou, R.-H.; Chen, C.-Y.; Chen, I.C.; Huang, H.-L.; Lu, Y.-W.; Kuo, C.-S.; Chang, C.-C.; Huang, P.-H.; Chen, J.-W.; Lin, S.-J. Trimethylamine N-Oxide, Circulating Endothelial Progenitor Cells, and Endothelial Function in Patients with Stable Angina. Scientific Reports 2019, 9, 4249, doi:10.1038/s41598-019-40638-y. DOI: https://doi.org/10.1038/s41598-019-40638-y
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
